FDA Highlights Systemic Issues at Mylan Laboratories in Recent Warning
FDA warns Mylan Laboratories for critical cGMP violations in quality control, data integrity, and governance, urging urgent corrective actions to ensure compliance.
FDA Warning Letter: MedOffice Saglik Endustri Anonim Sirketi
he FDA inspection at MedOffice Saglik Endustri Anonim Sirketi revealed significant CGMP violations that could jeopardize product quality and consumer safety. Issues ranged from inadequate testing of drug products to…
FDA Warning Letter Analysis: Diamond Chemical Co., Inc.
FDA issues a Warning Letter to Diamond Chemical Co., Inc. for cGMP violations, highlighting deficiencies in component testing, batch release, process validation, and stability testing. Explore the corrective actions and…
FDA Issues Warning Letter to LS Promotions Inc. for cGMP Violations
FDA issues warning to LS Promotions Inc. for significant cGMP violations. Learn about the key deficiencies, recommended CAPA plan, and steps for compliance.
FDA Issues Warning Letter Due to cGMP Violations
FDA issues warning to for CGMP violations. Addressing insanitary conditions, quality control, lab testing, and component verification.